

20 July 2015

Company Announcements Office Australian Securities Exchange 20 Bridge Street Sydney NSW 2000

ASX Announcement

Appointment of Non-Executive Director: Mr David Manning

Pulse Health Limited ("Pulse"; ASX Code: PHG) is pleased to announce the appointment of Mr David Manning as a Non-Executive Director of Pulse. Mr Manning has over 35 years of healthcare leadership and management experience in the surgery centre sector.

Pulse's strategy is to grow via acquisition or development of niche specialist private hospitals or surgery centres. The company's current takeover offer for ASX-listed Vision Eye Institute Limited (ASX Code: VEI), with eight day surgery centres as key assets within that business, is one component of the execution of this strategy.

The Pulse board is excited about the capability Mr Manning brings to the Board in relation to this strategy, and his appointment is not conditional on the success of the VEI takeover bid.

Mr Manning is the co-founder of Practice Development Associates in the US, which constructed over 75 new surgery centres. Practice Development Associates grew to become AmSurg Corp ("AmSurg"), now a US\$3.4b NASDAQ listed company operating 248 day surgery centres across the US. AmSurg is the largest eye surgery centre operator in the US.

Until December 2014, Mr Manning held the role of Executive Vice President and Chief Development Officer at AmSurg. Pulse's Chairman, Mr Stuart James said "We welcome David to the board of Pulse. His extensive healthcare experience will bring a wealth of knowledge to Pulse as the company pursues its growth strategy, particularly in the surgery centre market."

Regarding his appointment to the board Mr Manning said "I am delighted to be joining the Pulse board. Pulse is well positioned with a number of attractive growth opportunities, and I look forward to assisting the board and management with execution of the growth strategy".

Pulse is progressing the documentation of the services agreement with an entity controlled by Mr Manning as outlined in its replacement bidder's statement lodged on 17 July 2015. Pulse will update the market in due course.

Stuart James

Chairman
Pulse Health Limited

For further enquiries, please contact:

Phillipa Blakey Managing Director & CEO Pulse Health

Tel: +61 2 8262 6300

David Franks
Company Secretary
Pulse Health

Tel: +61 2 9299 9690

For more information of **Pulse Health** please visit <u>www.pulsehealth.net.au</u>

Pulse Health Limited

ACN: 104 113 760

20 July 2015

Company Announcements Australian Securities Exchange Level 2 120 King Street MELBOURNE VIC 3000



Norton Rose Fulbright Australia ABN 32 720 868 049 Level 15, RACV Tower 485 Bourke Street MELBOURNE VIC 3000 AUSTRALIA

Tel +61 3 8686 6000 Fax +61 3 8686 6505 GPO Box 4592, Melbourne VIC 3001 DX 445 Melbourne nortonrosefulbright.com

Direct line +61 3 8686 6710

Email

james.stewart@nortonrosefulbright.com

Our reference: 2828489

Dear Sir/Madam

Off-market takeover bid by Pulse Health Limited – Second Supplementary Bidder's Statement

We refer to the bidder's statement issued by Pulse Health Limited ABN 69 104 113 760 (**Pulse**) on 6 July 2015, as replaced by the bidder's statement dated 17 July 2015 and supplemented by the first and second supplementary bidder's statement, both dated 17 July 2015 (**Bidder's Statement**), in relation to Pulse's offmarket takeover bid for all of the ordinary voting shares in Vision Eye Institute Limited ABN 21 098 890 816 (**Vision**).

On behalf of Pulse and in accordance with section 647(3)(b) of the *Corporations Act 2001* (Cth), we **enclose** a copy of a third supplementary bidder's statement dated 20 July 2015 (**Third Supplementary Bidder's Statement**), which supplements Pulse's Bidder's Statement.

The Third Supplementary Bidder's Statement was lodged with ASIC and provided to Vision today.

Yours faithfully

James Stewart

Partner

Norton Rose Fulbright Australia

Encl.



Pulse Health Limited

Third Supplementary Bidder's Statement

1 Introduction

This document is the third supplementary bidder's statement (**Third Supplementary Bidder's Statement**) to the Bidder's Statement dated 6 July 2015, as replaced by the Replacement Bidder's Statement dated 17 July 2015, (**Original Bidder's Statement**) issued by Pulse Health Limited ABN 69 104 113 760 (**Pulse**) in relation to its off-market takeover bid for all of the ordinary voting shares in Vision Eye Institute Limited ABN 21 098 890 816 (**Vision**).

This Third Supplementary Bidder's Statement is given pursuant to Division 4 of Part 6.5 of the *Corporations Act* 2001 (Cth) (**Corporations Act**) in compliance with the requirements of section 643 of the Corporations Act.

This Third Supplementary Bidder's Statement supplements and is to be read together with the Original Bidder's Statement, the first supplementary bidder's statement dated 17 July 2015 and the second supplementary bidder's statement dated 17 July 2015. This document prevails in the event of any inconsistency with those documents.

1.1 Important notices

A copy of this Third Supplementary Bidder's Statement was lodged with the Australian Securities and Investments Commission (ASIC) on 20 July 2015. Neither ASIC nor any of its officers take any responsibility for the contents of this Third Supplementary Bidder's Statement.

1.2 **Defined terms and interpretation**

Unless the context otherwise requires, capitalised terms in this Third Supplementary Bidder's Statement have the same meaning given to them in section 16 of the Original Bidder's Statement. The rules of interpretation set out in section 16.2 of the Original Bidder's Statement also apply to this Third Supplementary Bidder's Statement, unless the context otherwise requires.

2 Announcement by Pulse in relation to the Takeover Bid

Attached to this Third Supplementary Bidder's Statement as Annexure A is an announcement made by Pulse on the ASX Market Announcements Platform on 20 July

2015 in relation to the appointment of Mr David Manning as a non-executive director of Pulse (ASX Announcement).

The ASX Announcement forms part of this Third Supplementary Bidder's Statement.

A copy of the ASX Announcement is also available at www.asx.com.au (Pulse ASX Code: PHG).

3 Consents

The persons listed in the table below have given and have not, before the lodgement of this Third Supplementary Bidder's Statement with ASIC, withdrawn their written consent to the inclusion of their respective statements noted next to their names and the references to those statements in the form and context in which they are included in this Third Supplementary Bidder's Statement:

Person	Named as	Statements
Mr Stuart James	Chairman of Pulse Health Limited	Quote from Mr Stuart James included in the ASX Announcement
Mr David Manning	Recently appointed Non- executive Director of Pulse Health Limited	Quote from Mr David Manning included in the ASX Announcement

Other than in relation to Mr Stuart James in his capacity as Chairman of Pulse, none of these persons have caused or authorised the issue of this Third Supplementary Bidder's Statement or have in any way been involved in the making of the Offer. The Offer is made by Pulse.

4 Approval of Third Supplementary Bidder's Statement

This Third Supplementary Bidder's Statement has been approved by a unanimous resolution passed by the Directors of Pulse.

This Third Supplementary Bidder's Statement is dated 20 July 2015, which is the date it was lodged with ASIC.

Stuart James Chairman, Pulse Health Limited

Annexure A - ASX Announcement



20 July 2015

Company Announcements Office Australian Securities Exchange 20 Bridge Street Sydney NSW 2000

ASX Announcement

Appointment of Non-Executive Director: Mr David Manning

Pulse Health Limited ("Pulse"; ASX Code: PHG) is pleased to announce the appointment of Mr David Manning as a Non-Executive Director of Pulse. Mr Manning has over 35 years of healthcare leadership and management experience in the surgery centre sector.

Pulse's strategy is to grow via acquisition or development of niche specialist private hospitals or surgery centres. The company's current takeover offer for ASX-listed Vision Eye Institute Limited (ASX Code: VEI), with eight day surgery centres as key assets within that business, is one component of the execution of this strategy.

The Pulse board is excited about the capability Mr Manning brings to the Board in relation to this strategy, and his appointment is not conditional on the success of the VEI takeover bid.

Mr Manning is the co-founder of Practice Development Associates in the US, which constructed over 75 new surgery centres. Practice Development Associates grew to become AmSurg Corp ("AmSurg"), now a US\$3.4b NASDAQ listed company operating 248 day surgery centres across the US. AmSurg is the largest eye surgery centre operator in the US.

Until December 2014, Mr Manning held the role of Executive Vice President and Chief Development Officer at AmSurg. Pulse's Chairman, Mr Stuart James said "We welcome David to the board of Pulse. His extensive healthcare experience will bring a wealth of knowledge to Pulse as the company pursues its growth strategy, particularly in the surgery centre market."

Regarding his appointment to the board Mr Manning said "I am delighted to be joining the Pulse board. Pulse is well positioned with a number of attractive growth opportunities, and I look forward to assisting the board and management with execution of the growth strategy".

Pulse is progressing the documentation of the services agreement with an entity controlled by Mr Manning as outlined in its replacement bidder's statement lodged on 17 July 2015. Pulse will update the market in due course.

Stuart James

Chairman
Pulse Health Limited

For further enquiries, please contact:

Phillipa Blakey David Franks



Managing Director & CEO Pulse Health Tel: +61 2 8262 6300 Company Secretary Pulse Health Tel: +61 2 9299 9690

For more information of **Pulse Health** please visit <u>www.pulsehealth.net.au</u>